Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ATATTOthis companyAttovia Therapeutics, Inc.	$15.87	-15.42×	6.25×	698.03×	-13.67×	-93.5%	40.4%	-4974.7%	-4490.9%	-40.2%	-42.8%	-6.5%	0.03×	0.53×	0×	14.2×	0.0%	—	—	2	C
ACRSAclaris Therapeutics, Inc.	$3.95	-5.68×	3.58×	47.18×	-5.45×	-122.2%	73.3%	-975.9%	-829.6%	-63.0%	-57.7%	-12.8%	0.02×	0.28×	0×	5.28×	0.0%	2	-2.65	1	D+
ALMSAlumis Inc.	$6.03	-4.21×	27.54×	345.07×	-33.2×	-85.0%	85.5%	-1776.3%	-1011.7%	-80.8%	-120.2%	-4.5%	0.12×	0.21×	0×	4.34×	0.0%	2	0.06	1	C-
ANABAnaptysBio, Inc.	$46.78	-70.26×	24.14×	3.83×	9.73×	-639.3%	99.0%	20.4%	-5.6%	-35.6%	14.6%	2.2%	0.38×	-3.24×	0.6×	9.07×	0.0%	5	2.21	3	B
CNTBConnect Biopharma Holdings Limited	$0.74	-2.82×	3.74×	2,452.52×	-2.19×	-15.8%	100.0%	-90740.6%	-86687.5%	-132.2%	-135.7%	-32.9%	0.02×	0.69×	0×	3.74×	0.0%	2	-15.61	2	C+
EVMNEvommune, Inc.	$6.82	-1.53×	0.51×	8.08×	-0.79×	-2667.3%	100.0%	-623.6%	-529.8%	-33.5%	-39.1%	-73.0%	0.01×	0.53×	0×	8.57×	0.0%	4	4.4	2	C+
Peer median	—	-4.21×	3.74×	47.18×	-2.19×	-122.2%	99.0%	-975.9%	-829.6%	-63.0%	-57.7%	-12.8%	0.02×	0.28×	0×	5.28×	0.0%	2	0.06	2	—